Skip to main content
Premium Trial:

Request an Annual Quote

Silence Issued Japanese Patent for Screening Drugs Against Cancer-Related Pathway

Premium

Silence Therapeutics said last week that it has received a Japanese patent covering methods for screening a therapeutic agent to treat diseases, such as cancer, related to increased Pl3-kinase pathway activity.

The patent, No. 4810095, specifically covers “the use of protein kinase N 3 for screening of therapeutic agents, thus preventing others from using PKN3 for screening purposes,” Silence said. “This new patent is broadly directed to various classes of therapeutic agents with the potential to impact the PI3-kinase pathway including short interfering RNA molecules, antibodies and small molecules, among others.”

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.